|
Feb 20
|
AstraZeneca Rises Almost 9% in a Month: How to Play the Stock
|
|
Feb 20
|
Ionis' Q4 Earnings and Sales Beat Estimates, Tryngolza Launch in Focus
|
|
Feb 20
|
FibroGen to Sell China Unit to AstraZeneca for $160 Million
|
|
Feb 20
|
Here’s Why AstraZeneca PLC (AZN) Traded Lower in Q4
|
|
Feb 20
|
AstraZeneca boosts China presence with FibroGen's anemia drug in $160 million deal
|
|
Feb 20
|
AstraZeneca deepens China presence with FibroGen deal
|
|
Feb 20
|
Q4 2024 Ionis Pharmaceuticals Inc Earnings Call
|
|
Feb 20
|
Luxury hotels group Firmdale has sold 20% stake to Swedish pharma tycoon
|
|
Feb 20
|
AstraZeneca Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
|
Feb 18
|
AstraZeneca boss takes home £15m pay packet after profits rise
|
|
Feb 18
|
AstraZeneca (LON:AZN) Is Posting Promising Earnings But The Good News Doesn’t Stop There
|
|
Feb 17
|
AstraZeneca’s Imfinzi bladder cancer regimen improves survival in Phase III trial
|
|
Feb 15
|
AstraZeneca: IMFINZI improved event-free survival, OS across MIBC
|
|
Feb 15
|
2 Healthcare Stocks That Tumbled in 2024...but Could See an Impressive Comeback in 2025
|
|
Feb 14
|
IMFINZI® (durvalumab) perioperative regimen improved event-free survival and overall survival across muscle-invasive bladder cancer patients regardless of complete pathology response status in post-hoc exploratory analysis of NIAGARA Phase III trial
|
|
Jan 29
|
FDA expands Enhertu approval to include HER2-ultralow breast cancer patients
|
|
Jan 29
|
Should AstraZeneca Stock Be in Your Portfolio Pre-Q4 Earnings?
|
|
Jan 29
|
Here's Why Astrazeneca (AZN) is a Strong Value Stock
|
|
Jan 28
|
FDA Expands Label of AZN's Enhertu for New Breast Cancer Indication
|
|
Jan 27
|
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies
|